-
Mashup Score: 2Preclinical Research on CRISPR-Based Gene Editing for Alzheimer Disease Treatment: Brent D. Aulston, PhD - 10 month(s) ago
The postdoctoral fellow at the University of California San Diego discussed using CRISPR-based gene editing to alter the amyloid precursor protein gene in mice models with symptoms of Alzheimer disease. [WATCH TIME: 5 minutes]
Source: Neurology LiveCategories: Future of Medicine, Latest HeadlinesTweet
-
Mashup Score: 0Increased Mortality Risk and Shorter Life Expectancy Associated With Sleeping Pills - 10 month(s) ago
Among sleeping pill nonusers, when compared with patients who got a medium amount of sleep, extremely short or long sleepers had approximately 30% higher risk of all-cause mortality and 3-5 years shorter life expectancy at age 30-50 years.
Source: Neurology LiveCategories: Latest Headlines, Partners & KOLsTweet-
Increased Mortality Risk and Shorter Life Expectancy Associated With Sleeping Pills - https://t.co/VsEznUFE48
-
-
Mashup Score: 0Building and Expanding Wearable Devices to Alleviate MS Symptoms: Valerie J. Block, PT - 11 month(s) ago
The adjunct instructor at the UCSF Weill Institute for Neurosciences provided perspective on the next steps in research for potential wearable devices focused on treating issues of multiple sclerosis. [WATCH TIME: 2 minutes]
Source: Neurology LiveCategories: Future of Medicine, Latest HeadlinesTweet-
Building and Expanding Wearable Devices to Alleviate MS Symptoms: Valerie J. Block, PT https://t.co/IyZF3CIRI2 https://t.co/MqYCL7jn1y
-
-
Mashup Score: 0Digital Health Assessments May Improve Parkinson Disease Diagnosis - 11 month(s) ago
Study shows that digital devices can provide objective and real-world measures of Parkinson disease, capturing key motor and nonmotor features of for early diagnosis of the neurodegenerative disorder.
Source: Neurology LiveCategories: Future of Medicine, Latest HeadlinesTweet-
Digital Health Assessments May Improve Parkinson Disease Diagnosis https://t.co/xyWMTgaR0V https://t.co/McmvxRLufn
-
-
Mashup Score: 1FDA Panel Votes in Favor of Gene Therapy SRP-9001 for Duchenne Muscular Dystrophy In Tight Decision - 12 month(s) ago
The FDA is set to make a final decision later this month and, if approved, SRP-9001 would be the first gene therapy specific to treat Duchenne muscular dystrophy.
Source: Neurology LiveCategories: Healthcare Professionals, Latest HeadlinesTweet-
RT @DrMTempest: https://t.co/DqeFQjgQ5x
-
-
Mashup Score: 0Dosing Begins for Phase 1 Study of Cell Therapy CK0803 in ALS - 1 year(s) ago
The 2-part study is intended to first establish safety and tolerability of multiple doses of CK0803, followed by efficacy analyses on several known ALS outcome measures.
Source: Neurology LiveCategories: Latest Headlines, Rare DiseaseTweet-
Dosing Begins for Phase 1 Study of Cell Therapy CK0803 in ALS https://t.co/VZ79KEiknp via @neurology_live
-
-
Mashup Score: 0Predicting Clinical Needs and Potential for Genetic Therapies in ALS: Jennifer Morganroth, MD, MBA - 1 year(s) ago
At the 2023 MDA’s Clinical and Scientific conference, the neurology resident at Penn Medicine talked about the challenges of delivering intrathecal therapies and the importance of planning clinical resources for patients with ALS. [WATCH TIME: 3 minutes]
Source: Neurology LiveCategories: Latest Headlines, Rare DiseaseTweet-
Predicting Clinical Needs and Potential for Genetic Therapies in ALS: Jennifer Morganroth, MD, MBA https://t.co/vis600hxaH via @neurology_live
-
-
Mashup Score: 0
The senior vice president of research at The ALS Association talked about the complexities of ALS and the importance of collaboration in research at the 2023 MDA conference. [WATCH TIME: 5 minutes]
Source: Neurology LiveCategories: Latest Headlines, Rare DiseaseTweet-
“Collaboration” in ALS Land is code for “We’ll welcome you to work w us as long as you do it our way.” https://t.co/xNXzep5L8n via @neurology_live
-
-
Mashup Score: 1FDA Provides Feedback on NurOwn ALS Therapy, Requests More Data - 1 year(s) ago
The recommendation stems from recently published topline data which demonstrated a clinically meaningful treatment response compared to placebo but failed to meet statistical significance.
Source: Neurology LiveCategories: Latest Headlines, Rare DiseaseTweet-
Over 2 years ago. No new supportive data added from another trial or from hospital exemption program or from EA. Over 2 years of post hoc analyses and investor calls. FDA Provides Feedback on NurOwn ALS Therapy, Requests More Data https://t.co/MHlFpRnQoy via @neurology_live
-
-
Mashup Score: 2
As a recap from MDA 2023, get caught up on some of the latest news in neuromuscular diseases as the NeurologyLive® team shares some of our data updates.
Source: Neurology LiveCategories: Latest Headlines, Rare DiseaseTweet-
Recapping Research From 2023 MDA Clinical and Scientific Conference https://t.co/ld651vS3vN via @neurology_live
-
Exciting news at #AAIC2023! CRISPR-based gene therapy shows promise in mice, tackling both familial and sporadic Alzheimer's disease, paving way for universal applicability. The therapy targets specific gene sequences relevant to AD for precise targeting. https://t.co/dG6vX6wCVU